Abstract Search

ea0088003 | Abstracts | BES2022

A plasma miR-193b-365 signature predicts non-responsiveness to Lactococcus lactis-based antigen- specific immunotherapy in new-onset type 1 diabetes

Gabriele Sassi , Giada Licata , Giuliana Ventriglia , Darcy Ellis , Damme Niels Van , Yvan Saeys , Silvia Caluwaerts , Alessia Mori , Pieter Rottiers , Chantal Mathieu , Francesco Dotta , Conny Gysemans , Guido Sebastiani

Background and aims: Combining systemic immunomodulation with disease-relevant antigens could provide longer-term solutions for preventing and even reversing autoimmune type 1 diabetes (T1D). Our team established that a combination therapy (CT), composed of a short-course low-dose anti-CD3 treatment with oral delivery of genetically-modified Lactococcus lactis (L. lactis) bacteria secreting full proinsulin plus the anti- inflammatory cytokine IL-10 (LL-PINS+I...

0 shares

Endocrine Abstracts

A plasma miR-193b-365 signature predicts non-responsiveness to Lactococcus lactis-based antigen- specific immunotherapy in new-onset type 1 diabetes

BiosciAbstracts